Kuliah Blok Neoplasma_januari 2011

7/29/2019 Kuliah Blok Neoplasma_januari 2011

1/161

DIAGNOSTIC IMAGING

NEOPLASMA

Dr. Yanto Budiman, Sp.Rad., M.Kes

Bagian Radiologi FK/RS Atma JayaJakarta


2/161

Imaging is emerging as an important adjunct to

the clinical assessment of cancer, contributing

to :

Tumor detection,

Characterization,

Staging, Treatment planning and follow-up.


3/161

Imaging may be requested in the

following situations:

As a routine investigation at the time of presentation fordiagnostic and staging purposes.

To answer a specific clinical question in an individualpatient on cancer treatment.

As a routine investigation on patients being treated withestablished therapy (chemotherapy, radiotherapy).

As a surveillance tool in patients undergoing a watchand wait policy (e.g. testicular cancer).

Screeningas a mechanism to identify clinicallyoccult cancers (e.g. breast cancer)


4/161

Diagnostic Tools

Rontgen X-ray

USG

CT Scan

MRI

Nuclear Medicine


5/161

NUCLEAR MEDICINE : Gamma Camera

SPECT

PET Scan


6/161


7/161


8/161


9/161


10/161


11/161


12/161

Normal Bone Scan

Normal increased uptake in :

Growth plate

Kidney and bladder


13/161

Bone Metastase

(multiple hot nodule/spot)


14/161

Soft Tissue neoplasm


15/161

Key Points

X-rays always first line

Ultrasound best second test

MRI best overall for

Characterisation

Staging & extent

Progress evaluation


16/161

Role of Imaging

Confirmation

Mass? What mass?

Classification

Normal or variant

Developmental

Benign or non-aggressive

Indeterminate/Suspicious/Malignant

Staging & Extent

Progress and surveillance


17/161

Algorithm for ST Masses


18/161


19/161

Soft Tissue Tumours

Most masses are NOT tumours

Cysts, ganglia, bursae

Calcinosis, osteochondromatosis, myositis

Most soft tissue masses are benign

Estimated 100:1 benign:malignant

Risk of malignancy rises with age


20/161


21/161


22/161

MRI Best for Staging

Global overview of relationships

Lesion characterisation

Lesion extent

Detection of contrast enhancement

Blood supply, tissue necrosis

Suspicious components


23/161

Benign Masses

Sebaceous cyst

Intramuscular

lipoma


24/161

ST Calcinosis


25/161

Elbow Ganglion Cyst

Palpable Cystic

Mass


26/161

MFH

Solid indeterminate mass


27/161

Soft Tissue Chondrosarcoma

High signal heterogeneous mass with internal septations and

marked rim enhancement (MRI)


28/161

Conclusions

Imaging is not histology

Clinical evaluation critical

X-rays ALWAYS first

Ultrasound second

MRI next

Imaging classification before surgery


29/161

Bone Neoplasms


30/161

Diagnostic Algorithm for Bone Tumours

Bone Lesion X-Ray

Manage

&

Review

Yes

No

Benign?No

Malignant?

MRI or CT

??

Diagnostic

BIOPSY

Staging

Path-Rad Correlation

Variant?

Yes


31/161

Diagnostic Gamut

Developmental

Dysplastic/dystrophic

Traumatic

Metabolic

Infective

Ischaemic necrosis

Tumour-like conditions

Tumours


32/161

Why X-Rays?

Mandatory for MSK lesions

New bone formation

Periosteal reaction

Bone expansion & growthLesion boundaries

Host marginal reaction

Patterns of destruction Still the most specific imaging modality for

most bone lesions


33/161

Age at Diagnosis

Age Tumo urs

111 NNNeeeuuurrrooobbblllaaassstttooommmaaa

111111000 EEEwwwiiinnnggg sssaaarrrcccooommmaaa (((tttuuubbbuuulllaaarrr)))

111000333000 OOOsssttteeeooosssaaarrrcccooommmaaa,,, EEEwwwiiinnnggg (((ffflllaaattt )))

333000

444000 NNNHHHLLL,,, MMMFFFHHH,,, fffiiibbbrrrooosssaaarrrcccooommmaaa,,, GGGCCCTTT,,, pppaaarrrooosssttteeeaaalllooosssttteeeooosssaaarrrcccooommmaaa

444000+++ MMMeeetttaaassstttaaasssiiisss,,, mmmyyyeeelllooommmaaa,,, ccchhhooonnndddrrrooosssaaarrrcccooommmaaa


34/161

X-Ray Features

Pattern of bone destruction or sclerosis

Internal architecture & density

Expansion, endosteal scalloping

Periosteal reaction & new bone

formation

Soft tissue mass


35/161

X-ray Aggressive Features

Bone destruction

Geographic

Moth-eaten

Permeative

Interrupted periosteal reaction


36/161

X-ray Benign Features

Elongated growth pattern

Narrow zone of transition

Sclerotic margin

Dense focal sclerosis

Dense incorporated solid periosteal

reaction

RCC M t t i


37/161

RCC Metastasis

Ewings Sarcoma


38/161

Ewing s Sarcoma

Osteosarcoma


39/161

Osteosarcoma


40/161

Diaphyseal Aclasia

Nonossifying Fibroma


41/161

Nonossifying Fibroma

TUMORS AND TUMORLIKE


42/161

TUMORS AND TUMORLIKE

PROCESSES

1.METASTATIC BONE TUMORS

2.PRIMARY MALIGNANT BONE TUMOR

Multiple myeloma

Osteosarcoma

Ewings Sarcoma

3.PRIMARY QUASIMALIGNANT BONETUMOR

Giant Cell Tumor


43/161

4.PRIMARY BENIGN BONE TUMORS

Osteochondroma

Osteoma

Bone island Osteoid osteoma

Simple bone cyst

Aneurysmal bone cyst

Metastatic Bone Tumors


44/161

Metastatic Bone Tumors

General Consideration

The most common malignant tumors

CNS tumors and basal cell Ca rarely

Life threatening complication

Insidence

70% are metastatic, 30% are primary

In females 70% from breast Ca

In males 60% from prostate Ca

Metastatic.. (contd)


45/161

Metastatic.. (cont d)

Radiologic Features

Technetium bone scan

80% of all metastase are located in the

central or axial skeleton

- Spine and Pelvis being a most commonAlteration in bone density and architecture

75% osteolytic, moth eaten or permeative

15% osteoblasticPeriosteal respose is rare

Metastatic bone tumor


46/161

Metastatic bone tumor


47/161

Prostatic Metastases

Multiple myeloma


48/161

p y

Primary bone tumor

Bone scan are cold

Gross Osteoporosis may be the only early

sign

Punched out lesions

Preservation of pedicles

Multiple Myeloma


49/161

p y


50/161

Osteosarcoma


51/161

Ewings Sarcoma


52/161

g

Most cases occur in the 1025 age rangeMay mimic infection

Diaphyseal permeative lesion

Femur, tibia and fibulaOnion skinperiosteal response

Most common primary malignant bone

tumor to metastasize to bone

Ewings Sarcoma


53/161

onion-skin

Ewing s Sarcoma

Osteochondroma


54/161

Aneurysmal Bone Cyst


55/161


56/161


57/161


58/161

Respiratory Neoplasm

Pleural tumor


59/161

Pleural tumor

Benign

Lipoma

- Fibroma

- Angioma

Malignant

- Mesothelioma

- Sarcoma


60/161

Mesothelioma

* From the endothelial pleural layer

* 2 type: - Nodular : > often

- Diffuse haemorrhagic effusion

Metastase :

From bronchogenic Ca (40%)From Mammae Ca (20%)

From Lymphosarcoma (10%)

Mesothelioma


61/161

Pulmonary Carcinomaa. Bronchogenic Ca


62/161

a. Bronchogenic Ca- Most common

- Male > Female- Right > often

- Age : 5060 y.o.

- Related : Smoking, radioactive/industry material,TBC

- Classified into :

a. Central type

b. Perifer nodularc. Pneumonic type

d. Miliary type

BronchogenicCa


63/161

A Posteroanterior (PA) chest radiograph demonstrates a spiculated

right upper lobe mass.

B Chest CT (lung window) demonstrates a peripheral mass with spiculated

borders

b. Pancoasts tumor


64/161

b. Pancoast s tumor

Posterior superior pulmonary sulcus tumor

Posterior costae 1- 3 destruction with

vertebral erosion

Cervicalis symphatis paralysis Horner

syndrome

Pancoasts tumor


65/161

3 Alveolar cell ca


66/161

3. Alveolar cell ca

= Pulmonary adenomatosis

Female = Male

40 years

Ro:

Small nodules on both lung field with large masses

in right pulmonary base

No visible node enlargement but shows nodal

consolidation in perihiler Pleura ussualy not affected

Heart normal


67/161

4. Hamartoma


68/161

. a a to aOvergrowth of few tissue such as smooth

muscle fibrous cartilage tissue and vascular

Ro :

Round/oval/lobulated shadow with soft

tissue density, well-defined border, diameter

2.59 cm.

Calsification inside : pop corncalcification

Hamartoma


69/161

Metastastic tumor in lung


70/161

Emboli through pulmonaryartery &bronchial artery

From adjacent organ:

Oesophagus

Thyroid

Mammae


71/161

Metastase intrapulmonal


72/161

c. Milliary type


73/161

Thyroid Ca

Mammae CaSarcoma

Lung Ca

d. Pleural metastase : Pleura effusion

Mammae Ca

MesotheliomaLung Ca

e. Pneumonic type


74/161

Oesophagus

Lung

Mammae

f. Lymphatic type

Lung

Gaster

Mammae

Pancreas, etc.

Lymphatic type:Coarse reticular shadowing


75/161


76/161

GIT Diagnostic Tools:


77/161

Sialografi

Esophagograhi

Maagduodenographi

Colon in loop

Barium Follow Through CT Scan, MRI


78/161


79/161


80/161

Single Contrast Barium EnemaDouble Contrast Barium Enema

Abdominal Imaging


81/161

g g

In the hollow organ segments of the GI tract, contrastimaging studies remain the cornerstone in characterizingthe tumor, but lack the ability to stage the tumor, either interms of depth of penetration through the wall or indefining regional nodal involvement.

CT Scan remains the most widely used for axial imaging

Magnetic resonance imaging has shown only limitedadvantage over CT

Ca oesophagus


82/161

Tumours of the stomach


83/161

Benign tumours of the stomach:- Adenoma

- Leiomyoma

- Lipoma

- Abberant pancreas- Inflammatory polyps, etc

Location:

- pyloric portion (75%)

- body (20%)

- fundus & cardia (5%)

Radiographic appearances:


84/161

g p pp

- A sharply circumscribed filling defect

projecting within the lumen

Malignant tumors of the stomach:

Gross morphologic types:- Ulcerative (28%)

- Fungating/polypod (22%)

- Spreading/infiltrating (13%)

- Remainder unclassifiable

Usual histologic pattern: well-differentiated adenoca


85/161

Usual histologic pattern: well differentiated adenoca

Location: pyloric & prepyloric regions

Radiographic appearances:

1. Irregular filling defect.2. Malignant ulcer within the filling defect.

3. A leather bottle type stomach suggesting scirrhous

ca.


86/161

Ulcerative gastricadenocarcinoma


87/161

Polypoid gastric

adenocarcinoma.


88/161

leather bottle type

scirrhous ca.


89/161

Ulcerating leiomyoma


90/161


91/161


92/161

Spot image of adenocarcinoma of the duodenum presenting

as a classic tight annular apple core lesion in the second part

of the duodenum

Peripapillary adenocarcinoma of duodenum


93/161


94/161

Ductal adenocarcinoma of the pancreatic head.

unenhanced scan (A), CT shows an enlargement

of the head,within

which a hypodense mass is recognizable after

contrast medium

(B). The tumor looks smaller in the venous phase

due to the peripheral

enhancement (C)

SMALL Bowel :

Benign tumors and malignant tumors,


95/161

Benign tumours:- Adenoma

- Leiomyoma (the commonest)

Malignant tumours:

- Lymphoma (the commonest)

- Leiomyosarcoma- Carcinoid

- Metastases (malignant melanoma & bronchial ca)

Malignant lymphoma


96/161

Colorectal tumors

Polyps:

A l l ti


97/161

- A mucosal elevation

- Radiographic appearance:

* Bowler-hat sign

* En face: target sign

Colorectal cancer:

- The commonest cancers in western Europe & US

- Men = women

- Tumours tend to be right-sided- May be associated urinary tract & gynaecological

malignancy

Colorectal cancer


98/161

Virtual Endoscopy, using CT Scan


99/161

Colorectal cancer

Fungating type:


100/161

u g g ype:

- Medullary carcinoma

- Sites: caecum, ascending colon, rectum

- Complication: bleeding, fistula

Polypoid type:

- Sites: ascending colon usually

- Complication: Intussusception

Annular type:


101/161

- Mucoid adenocarcinoma, scirrhousfibrocarcinoma

- Sites: sigmoid, descending colon, flexures

- Complication: fistula, obstruction

Radiological appearances:

- Filling defect

- Obstruction


102/161

Polip colon


103/161

Liver malignancy


104/161

CT Scan

USG


105/161


106/161

Cranial Neoplasm

INTRACRANIAL MASSES


107/161

1. Radiografic Characteristic of Lesion

a. Intrinsic CT density

b. Contrast enhancement BBB(ring, gyriform, homogenous)

c. Multiple lesions

d. MR appearance

DD/ : Intracranial Mass

(TEACH )


108/161

( )

Tumor

EdemaAbcess, AVM, aneurysm

Cyst

Hematoma

A. Primary Tumor


109/161

1. Glioma

a. Astrocytoma

b. Ependymoma

c. Oligodendrogliomad. Ganglioglioma

2. Meningioma

3. Lymphoma

B. Metastatic Tumor


110/161


111/161

DIFFERENTIAL DIAGNOSIS BYLOCATION

Diagnosa banding berdasarkan pola


112/161

Enhancement lesi pada parenkim otakA. Cerebral parenchymal lesion

Ring : - Glioma

- Meta- Abcess

- Resolving hematoma

- Resolving infarctionHomogenous :

- Lymphoma

B.DD/ :

Intraventicular


113/161

Mass Lesion

Meningioma, Astrocytoma,

Choroid plexus papilloma,

Colloid cyst, Meta,

Ependymoma,

Subependymoma, AVM, Oligo,

Lymphoma

C.DD/: PinealRegion Mass

Germ cell tumor,


114/161

,

Pineal cell tumor

Germinoma,

Pineoblastoma,

Teratoma, Glial cell

tumor, Dermoid,

Epidermoid,

Choriocarcinoma,Meta

D.DD/Tumor di daerah Juxta Sellar and

Supra Sellar


115/161

Adenoma

CraniopharyngiomaAneurysm

Meningioma

Uncommon : Meta, Arachnoid

cyst, Glioma


116/161


117/161

Breast Neoplasm


118/161

Mamografi

USG

MRI


119/161

BIRADS Classification &Risk of CA Category 0, 4 & 5


120/161

Positive findings needing further action (10-80%

chance of cancer)

Category 1 & 2

Benign with


121/161

p g y

Palpable lesion, atypical FA, complex cyst etc.

Benign biopsy expected = discharge or short-term FU

4BIntermediate suspicion

Lesion with suspicious features

Benign biopsy = close correlation, ?re-biopsy

4CModerate suspicion

Not classic for CA Prominent suspicious features

Benign biopsy not expected = should re-biopsy or excise

BIRADS 3 & ScreeningAssessment BIRADS 3 is refuge for indecision


122/161

Intended for highly likely to be benign, but I am justmaking sure

Appropriate in setting with no biopsy facilities

Implemented by 6-12 month followup

BIRADS 3 has wide variability of application

Depends on individual level of uncertainty

UK and Australian practice

No place in formal assessment centre

Logistic problems, great anxiety, low yield

Determine if benign (Cat 1, 2) or needs biopsy (Cat 4, 5)

Cat 3 actively discouraged

MAMMOGRAPHY


123/161

X R d i d h


124/161

X-Ray dosis rendah Massa < 5 mm

Massa tidak teraba

Tanda keganasan

Check-up post operasi

Tidak invasif

Indikasi:B j l


125/161

Benjolan

Rasa tidak enak pada mammae

Keluarnya cairan dari puting susu

Kelainan kulit mammae

Cancer Phobia

Post operasi

Skrining

Mengapa Skrining Harus Dilakukan ?

C

i 35 th


126/161

Ca mammae > usia 35 th

Kapan Skrining Diperlukan?

Usia 35 th Usia 3550 th 2 atau 3 th Usia > 50 th Setiap tahun


127/161


128/161


129/161


130/161


131/161

Kriter ia Keganasan


132/161

Tanda Primer:

Lesi Radioopak irreguler

Mikrokalsifikasi

Tanda Sekunder:

P b l & t k i k lit


133/161

Penebalan & retraksi kulit

Vaskularisasi

Posisi papila & areola berubah

Jar. fibroglandular tidak teratur

Distorsi lemak retromammae

Metastasis KGB aksila

Mammogram

Batas tegasBatas tegas/

Irregular

Densitas lemak?


134/161

Densitas lemak?

Ya Tidak

Lipoma, fat necrosisHamartoma

Galactocele, LNUSG

Anechoic kompleks

Solid

Kista Hematoma, Papillary

Tumor

Fibroadenoma

Phyllodes tumor

Abscess

Hematoma

Fat necrosis

Scleroing adenosis

Radial scarPost surgical scar

Batas tegas? Ya

Densitas lemak ? Tidak

USG? Anechoic


135/161

Kista

Fibroadenoma

Batas tegas? Ya



136/161


USG? Hipoechoic


137/161

Vascular calcification


138/161


139/161

Rim calcification Lucent calcificationDermal calcification


140/161

Dermal calcification


141/161


142/161

ULTRASONOGRAPHY


143/161


144/161


145/161

Gambaran USG lesi payudara


146/161

Gambaran USG lesi payudara

Tanda pr imer :

Batas Bentuk

Pola ekho

Bayangan retro tumor

Tanda Sekunder

Penebalan kulit


147/161

e eb u

Perubahan jaringan

Kekakuan Lig. Cooperi

Tes Dinamik

Efek kompresi

Mobilitas


148/161

Arah scanningUSG payudara


149/161

TECHNIQUE


150/161

USG Colour Doppler nilai vaskularisasitumor payudara.

L i


151/161

Lesi ganas =

feeding vessel

pembuluh darah bagian perifer lesi

tumourvessel

pembuluh darah yang terletak didalam lesi payudara


152/161


153/161


154/161


155/161

Malignant Lesion


156/161


157/161


158/161


159/161


160/161


161/161

Date post:	14-Apr-2018
Category:	Documents
Upload:	natallia-batuwael
View:	224 times
Download:	0 times

Kuliah Blok Neoplasma_januari 2011

Documents